InViragen Advances DENVax into Second Stage of Ongoing Phase 2 Clinical Study
2/27/2013 11:07:23 AM
FORT COLLINS, Colo.--(BUSINESS WIRE)--Inviragen, Inc. today announced the initiation of the second stage of an ongoing Phase 2, randomized, double-blind, placebo-controlled study of DENVax™, the Company’s investigational dengue vaccine. An independent data and safety monitoring board (DSMB) evaluated the preliminary safety data from the first stage of the Phase 2 trial, in which individuals in multiple age groups received either DENVax vaccine or placebo. Upon the review and the recommendation of the DSMB, Inviragen is advancing DENVax into the second stage of this clinical trial. In this second stage, DENVax will be tested for safety and immunogenicity in approximately 200 additional children aged 18 months to 11 years.